A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation
Clinical trial NCT03182244 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03182244
- Sponsor
- Astellas Pharma Inc
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-10-25
- Primary completion
- 2023-12-25
- Enrollment
- 276
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.